Benzinga | Oct 20, 2021 06:06AM EDT

HC Wainwright & Co. Initiates Coverage On Compass Therapeutics with Buy Rating, Announces Price Target of $11

HC Wainwright & Co. analyst Michael King initiates coverage on Compass Therapeutics (OTC:CMPX) with a Buy rating and announces Price Target of $11.